Janney Montgomery Scott LLC Acquires 4,482 Shares of Exelixis, Inc. (NASDAQ:EXEL)

Janney Montgomery Scott LLC lifted its holdings in Exelixis, Inc. (NASDAQ:EXEL) by 13.5% in the 1st quarter, Holdings Channel.com reports. The firm owned 37,778 shares of the biotechnology company’s stock after acquiring an additional 4,482 shares during the quarter. Janney Montgomery Scott LLC’s holdings in Exelixis were worth $1,395,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. Farther Finance Advisors LLC raised its stake in Exelixis by 6.1% in the first quarter. Farther Finance Advisors LLC now owns 5,372 shares of the biotechnology company’s stock valued at $195,000 after buying an additional 307 shares during the last quarter. Balyasny Asset Management L.P. raised its stake in Exelixis by 1.9% in the fourth quarter. Balyasny Asset Management L.P. now owns 17,203 shares of the biotechnology company’s stock valued at $573,000 after buying an additional 317 shares during the last quarter. Steward Partners Investment Advisory LLC raised its stake in Exelixis by 4.9% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 7,050 shares of the biotechnology company’s stock valued at $235,000 after buying an additional 330 shares during the last quarter. Oregon Public Employees Retirement Fund raised its stake in Exelixis by 0.6% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 58,159 shares of the biotechnology company’s stock valued at $1,937,000 after buying an additional 354 shares during the last quarter. Finally, Principal Securities Inc. raised its stake in Exelixis by 62.8% in the fourth quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company’s stock valued at $32,000 after buying an additional 373 shares during the last quarter. Hedge funds and other institutional investors own 85.27% of the company’s stock.

Exelixis Stock Up 1.3%

Exelixis stock opened at $43.67 on Friday. The firm has a market cap of $11.91 billion, a price-to-earnings ratio of 19.85, a price-to-earnings-growth ratio of 0.86 and a beta of 0.28. Exelixis, Inc. has a 52 week low of $21.82 and a 52 week high of $49.62. The business’s 50-day moving average price is $41.07 and its 200 day moving average price is $37.33.

Insider Buying and Selling

In other Exelixis news, Director Jack L. Wyszomierski sold 7,535 shares of the firm’s stock in a transaction that occurred on Tuesday, June 3rd. The stock was sold at an average price of $43.09, for a total value of $324,683.15. Following the sale, the director now directly owns 358,882 shares of the company’s stock, valued at approximately $15,464,225.38. This trade represents a 2.06% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Dana Aftab sold 1,508 shares of the firm’s stock in a transaction that occurred on Thursday, May 1st. The shares were sold at an average price of $39.00, for a total value of $58,812.00. Following the completion of the sale, the executive vice president now directly owns 693,181 shares in the company, valued at approximately $27,034,059. The trade was a 0.22% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 458,113 shares of company stock valued at $21,024,817 over the last ninety days. Company insiders own 2.82% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on EXEL shares. Benchmark reiterated a “neutral” rating on shares of Exelixis in a research note on Monday. Stephens upgraded Exelixis from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $29.00 to $60.00 in a research note on Tuesday. Wall Street Zen cut Exelixis from a “strong-buy” rating to a “buy” rating in a research note on Thursday, May 15th. Bank of America increased their price objective on Exelixis from $45.00 to $46.00 and gave the company a “neutral” rating in a report on Thursday, June 5th. Finally, Royal Bank Of Canada reissued an “outperform” rating and issued a $40.00 price objective on shares of Exelixis in a report on Wednesday, May 14th. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating and fourteen have assigned a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $43.22.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.